CSL Ltd ADR CSLLY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
-
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
-
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
-
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
-
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
-
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
-
CSL Joins Accumulus Synergy to Drive Industry Change
-
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Trading Information
- Previous Close Price
- $98.94
- Day Range
- $98.28–99.00
- 52-Week Range
- $71.51–109.00
- Bid/Ask
- $97.62 / $98.89
- Market Cap
- $95.72 Bil
- Volume/Avg
- 16,180 / 18,890
Key Statistics
- Price/Earnings (Normalized)
- 31.36
- Price/Sales
- 6.52
- Dividend Yield (Trailing)
- 1.34%
- Dividend Yield (Forward)
- 1.34%
- Total Yield
- 1.34%
Company Profile
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 30,000
- Website
- https://www.csl.com
Competitors
Valuation
Metric
|
CSLLY
|
PFE
|
4502
|
---|---|---|---|
Price/Earnings (Normalized) | 31.36 | 20.96 | 16.04 |
Price/Book Value | 5.50 | 1.85 | 0.85 |
Price/Sales | 6.52 | 2.90 | 1.52 |
Price/Cash Flow | 34.67 | 21.18 | 7.61 |
Price/Earnings
CSLLY
PFE
4502
Financial Strength
Metric
|
CSLLY
|
PFE
|
4502
|
---|---|---|---|
Quick Ratio | 0.87 | 0.51 | 0.66 |
Current Ratio | 2.18 | 0.86 | 1.26 |
Interest Coverage | 8.01 | −0.88 | 1.21 |
Quick Ratio
CSLLY
PFE
4502
Profitability
Metric
|
CSLLY
|
PFE
|
4502
|
---|---|---|---|
Return on Assets (Normalized) | 7.82% | 3.50% | 2.91% |
Return on Equity (Normalized) | 17.33% | 8.28% | 6.11% |
Return on Invested Capital (Normalized) | 10.52% | 5.39% | 4.29% |
Return on Assets
CSLLY
PFE
4502
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Kdrcxsvlyh | Bktzn | $512.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Dkpkqcmbw | Szcggq | $117.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Cdbxyvjj | Nzqvqf | $111.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Sszmsgzw | Zwhtcw | $34.4 Bil | |||
argenx SE ADR
ARGX
| Lskvgrmx | Xsyb | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Nmyyzfwvr | Jvyzy | $29.2 Bil | |||
Moderna Inc
MRNA
| Pbtwsmymz | Jkpxc | $23.1 Bil | |||
United Therapeutics Corp
UTHR
| Shxrhqzr | Mdfb | $15.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Dljlqsxh | Hmlkcv | $13.2 Bil | |||
Incyte Corp
INCY
| Lmfrjxnbs | Svgqbkl | $13.0 Bil |